Dhaka, Dec. 29 -- Trading of Global Depositary Receipts (GDRs) for Beximco Pharmaceuticals Limited, one of Bangladesh's largest drug manufacturers, is set to be suspended on the London Stock Exchange (LSE) starting from January 2, 2026.

The suspension comes after the company failed to publish its audited financial reports for the fiscal year ending June 30, 2024-25 within the mandatory time frame.

According to a disclosure on the LSE website, Beximco Pharma was unable to release its final annual results by the December 31, 2025 deadline required under the London Stock Exchange's Alternative Investment Market (AIM). Consequently, the exchange is moving to temporarily halt the trading of the company's GDRs.

The company cited ongoing lega...